EnginZyme secures 6.4 M€ investment to accelerate the development of its technology platform
Type of post: NEWS IN BRIEF.
EnginZyme
has announced a Series A investment of 6.4 M€ led by Sofinnova Partners that will be
used to accelerate the development of its technology platform and take its
first internal production process to pilot.
Press release (Business Wire): “EnginZyme Secures €6.4 Million
Series A Financing Round Led by Sofinnova Partners”, 22/4/2020.
Figure 1. EnginZyme secures 6.4 M€ investment
to accelerate the development of its technology platform
EnginZyme, the cell-free synthetic biology
company, was founded in Stockholm (Sweden) in 2014. Since its start, it has
used its technology to provide R&D services to leading companies in
multiple industries, such as pharma, food, chemicals and flavors &
fragrances. The company seeks to solve one of the fundamental problems of our
time: How to produce sustainable alternatives to plastics, nylons, rubbers, and
the tons of other synthetics that are used on a daily basis, without
compromising on cost-effectiveness. To achieve this, EnginZyme’s technology
platform combines the breadth and power of nature (enzymatic cascades) with the
efficiency of the chemical industry (packed bed reactors).
Dr. Engelmark Cassimjee (EnginZyme CEO) said: “It
has long been recognized that if we could effectively access nature’s full
palette of molecules, we could solve many of the world’s most pressing problems.
There’s just so much more you can do with biological systems than with
traditional catalysts and petroleum-based building blocks. But the key word
here is ‘effectively’ – it needs to be as cheap and easy to scale as the
chemical solutions we’ve used for more than a century now. We’re the first
company to truly address that and by doing so we are building foundational
technology for an entire future industry.”